• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Therapy of chronic relapsing thrombotic thrombocytopenic purpura with prednisone and azathioprine.

作者信息

Moake J L, Rudy C K, Troll J H, Schafer A I, Weinstein M J, Colannino N M, Hong S L

出版信息

Am J Hematol. 1985 Sep;20(1):73-9. doi: 10.1002/ajh.2830200110.

DOI:10.1002/ajh.2830200110
PMID:3875285
Abstract

As a 51-year-old woman recovered from an initial acute episode of thrombotic thrombocytopenic purpura (TTP), her plasma was found to contain unusually large von Willebrand factor (vWF) multimers. Clinical, hematological, and vWF studies of her siblings and children were normal. The unusually large vWF forms were presumably derived from endothelial cells, persisted in her plasma after recovery, and were associated with recurrent episodes of TTP during the subsequent 6 months. After the last episode of relapse they disappeared from her plasma following 3 1/2 weeks of therapy with prednisone and did not return during 17 months of treatment with prednisone and/or azathioprine. She is now receiving no drugs, has normal plasma vWF forms, and has not had any more episodes of TTP. We conclude that our patient had an acquired defect in the conversion of unusually large vWF multimers derived from endothelial cells to the somewhat smaller vWF forms usually present in circulation. The defect may have been immune-mediated, because it was eliminated during therapy with immunosuppressive drugs.

摘要

相似文献

1
Therapy of chronic relapsing thrombotic thrombocytopenic purpura with prednisone and azathioprine.
Am J Hematol. 1985 Sep;20(1):73-9. doi: 10.1002/ajh.2830200110.
2
Abnormalities of von Willebrand factor multimers in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.血栓性血小板减少性紫癜和溶血尿毒综合征中血管性血友病因子多聚体的异常。
Am J Med. 1989 Sep;87(3N):9N-15N.
3
Effects of fresh-frozen plasma and its cryosupernatant fraction on von Willebrand factor multimeric forms in chronic relapsing thrombotic thrombocytopenic purpura.新鲜冰冻血浆及其冷上清组分对慢性复发性血栓性血小板减少性紫癜中血管性血友病因子多聚体形式的影响。
Blood. 1985 May;65(5):1232-6.
4
Thrombotic thrombocytopenic purpura and the haemolytic-uraemic syndrome: evolving concepts of pathogenesis and therapy.血栓性血小板减少性紫癜与溶血尿毒综合征:发病机制与治疗的演变概念
Clin Haematol. 1986 May;15(2):413-42.
5
von Willebrand factor abnormalities and endothelial cell perturbation in a patient with acute thrombotic thrombocytopenic purpura.一名急性血栓性血小板减少性紫癜患者的血管性血友病因子异常与内皮细胞紊乱
Am J Med Sci. 1986 Jan;291(1):47-50. doi: 10.1097/00000441-198601000-00009.
6
Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP).利妥昔单抗用于治疗难治性/复发性血栓性血小板减少性紫癜(TTP)。
Am J Hematol. 2004 Oct;77(2):171-6. doi: 10.1002/ajh.20166.
7
Unrecognized pattern of von Willebrand factor abnormalities in hemolytic uremic syndrome and thrombotic thrombocytopenic purpura.溶血性尿毒症综合征和血栓性血小板减少性紫癜中血管性血友病因子异常的未被识别模式。
J Am Soc Nephrol. 1999 Jun;10(6):1234-41. doi: 10.1681/ASN.V1061234.
8
Chronic relapsing thrombotic thrombocytopenic purpura in infants with large von Willebrand factor multimers during remission.缓解期伴有大血管性血友病因子多聚体的婴儿慢性复发性血栓性血小板减少性紫癜
J Pediatr. 1992 Jan;120(1):49-53. doi: 10.1016/s0022-3476(05)80596-7.
9
Thrombotic thrombocytopenic purpura: understanding a disease no longer rare.血栓性血小板减少性紫癜:认识一种不再罕见的疾病。
Am J Med Sci. 1998 Aug;316(2):105-19. doi: 10.1097/00000441-199808000-00006.
10
alpha 1-Antitrypsin therapy in a case of thrombotic thrombocytopenic purpura.α1抗胰蛋白酶治疗血栓性血小板减少性紫癜1例
Lancet. 1995 Jan 28;345(8944):224-5. doi: 10.1016/s0140-6736(95)90224-4.

引用本文的文献

1
Immune Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, Therapy and Open Issues.免疫性血栓性血小板减少性紫癜:病理生理学、诊断、治疗及未解决的问题。
Mediterr J Hematol Infect Dis. 2024 Jul 1;16(1):e2024060. doi: 10.4084/MJHID.2024.060. eCollection 2024.
2
Real-World Data Analysis of Patients Affected by Immune-Mediated Thrombotic Thrombocytopenic Purpura in Italy.意大利免疫介导性血栓性血小板减少性紫癜患者的真实世界数据分析
J Clin Med. 2024 Feb 27;13(5):1342. doi: 10.3390/jcm13051342.
3
Management of acquired, immune thrombocytopenic purpura (iTTP): beyond the acute phase.
获得性免疫性血小板减少性紫癜(iTTP)的管理:急性期之后
Ther Adv Hematol. 2022 Jul 26;13:20406207221112217. doi: 10.1177/20406207221112217. eCollection 2022.
4
Efficacy and safety of azathioprine during remission of immune-mediated thrombotic thrombocytopenic purpura.硫唑嘌呤在免疫介导的血栓性血小板减少性紫癜缓解期的疗效及安全性
Blood Adv. 2022 Sep 27;6(18):5463-5466. doi: 10.1182/bloodadvances.2022007632.
5
Unresponsive Thrombotic Thrombocytopenic Purpura (TTP): Challenges and Solutions.无反应性血栓性血小板减少性紫癜(TTP):挑战与解决方案
Ther Clin Risk Manag. 2021 Jun 3;17:577-587. doi: 10.2147/TCRM.S205632. eCollection 2021.
6
Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura.血栓性血小板减少性紫癜患者临床护理的良好实践声明(GPS)
J Thromb Haemost. 2020 Oct;18(10):2503-2512. doi: 10.1111/jth.15009. Epub 2020 Sep 11.
7
Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis.利妥昔单抗治疗急性难治性或慢性复发性非家族性特发性血栓性血小板减少性紫癜的疗效:系统评价与汇总数据分析。
J Thromb Thrombolysis. 2012 Oct;34(3):347-59. doi: 10.1007/s11239-012-0723-9.
8
Treatment of resistant thrombotic thrombocytopenic purpura with rituximab and cyclophosphamide.利妥昔单抗联合环磷酰胺治疗难治性血栓性血小板减少性紫癜
Int J Hematol. 2004 Jul;80(1):94-6. doi: 10.1532/ijh97.e0403.
9
von Willebrand factor mediates platelet adhesion to virally infected endothelial cells.
Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5153-6. doi: 10.1073/pnas.90.11.5153.